Skip to main content

Main menu

  • Content
    • Current Issue
    • Advance Access
    • Archive
    • Supplements
    • Special Collections
    • Topic Collections
  • For Authors
    • Instructions for Authors
    • Tips for Writing About Programs in GHSP
      • Local Voices Webinar
      • Connecting Creators and Users of Knowledge
    • Submit Manuscript
    • Publish a Supplement
    • Promote Your Article
    • Resources for Writing Journal Articles
  • About
    • About GHSP
    • Editorial Team
    • Advisory Board
    • FAQs
    • Instructions for Reviewers

User menu

  • My Alerts

Search

  • Advanced search
Global Health: Science and Practice
  • My Alerts

Global Health: Science and Practice

Dedicated to what works in global health programs

Advanced Search

  • Content
    • Current Issue
    • Advance Access
    • Archive
    • Supplements
    • Special Collections
    • Topic Collections
  • For Authors
    • Instructions for Authors
    • Tips for Writing About Programs in GHSP
    • Submit Manuscript
    • Publish a Supplement
    • Promote Your Article
    • Resources for Writing Journal Articles
  • About
    • About GHSP
    • Editorial Team
    • Advisory Board
    • FAQs
    • Instructions for Reviewers
  • Alerts
  • Find GHSP on LinkedIn
  • Visit GHSP on Facebook
  • RSS
EDITORIAL
Open Access

Long-Acting HIV Treatment and Prevention: Closer to the Threshold

Matthew Barnhart
Global Health: Science and Practice June 2017, 5(2):182-187; https://doi.org/10.9745/GHSP-D-17-00206
Matthew Barnhart
aAssociate Editor, Global Health: Science and Practice, and Medical Officer, U.S. Agency for International Development, Washington, DC, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mbarnhart@ghspjournal.org
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • Comments
  • PDF
Loading

Figures & Tables

Tables

    • View popup
    TABLE. Antiretrovirals With Long-Acting Potential: Illustrative Examples from Different Drug Classes
    Drug ClassARV NameDevelopment PhaseCompany
    Non-Nucleoside
    Reverse Transcriptase Inhibitor
    RilpivirinePhase III injectable (oral agent approved)Janssen
    Integrase InhibitorCabotegravirPhase III injectableViiV
    Nucleoside/Nucleotide
    Reverse Transciptase
    Inhibitor (NRTI)
    EFdAPhase IMerck
    Tenofovir alafenamide fumarate (TAF)Preclinical implant (oral agent approved)Gilead
    GS-9131Preclinical/Phase IGilead
    Capsid InhibitorGS-CA1PreclinicalGilead
PreviousNext
Back to top

In this issue

Global Health: Science and Practice: 5 (2)
Global Health: Science and Practice
Vol. 5, No. 2
June 27, 2017
  • Table of Contents
  • About the Cover
  • Index by Author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Global Health: Science and Practice.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-Acting HIV Treatment and Prevention: Closer to the Threshold
(Your Name) has forwarded a page to you from Global Health: Science and Practice
(Your Name) thought you would like to see this page from the Global Health: Science and Practice web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long-Acting HIV Treatment and Prevention: Closer to the Threshold
Matthew Barnhart
Global Health: Science and Practice Jun 2017, 5 (2) 182-187; DOI: 10.9745/GHSP-D-17-00206

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Long-Acting HIV Treatment and Prevention: Closer to the Threshold
Matthew Barnhart
Global Health: Science and Practice Jun 2017, 5 (2) 182-187; DOI: 10.9745/GHSP-D-17-00206
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Statistics from Altmetric.com

Jump to section

  • Article
    • WHY WE NEED LONG-ACTING ANTIRETROVIRALS
    • TANGIBLE PROGRESS ON A 1- OR 2-MONTH INJECTABLE
    • NEW ARVS MAY HELP OVERCOME THESE DOWNSIDES
    • BROADLY NEUTRALIZING ANTIBODIES: A POSSIBLE ALTERNATIVE TO LONG-ACTING ARVS FOR PREVENTION
    • IMPLANTS THAT ARE EASIER TO IMPLEMENT: BIODEGRADABLE AND REFILLABLE APPROACHES
    • IMPROVED INJECTION APPROACHES: SIMPLIFYING ADMINISTRATION, REDUCING COST AND DISCOMFORT
    • COLLABORATIVE EFFORTS TO ADVANCE NEW ARVS
    • CONTINUING DOWN THE ROAD TO ULTIMATE SUCCESS
    • Acknowledgments
    • Notes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • Comments
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Supply Chain Workforce: The Foundation of Health Supply Chains
  • The Challenge Initiative: Lessons on Rapid Scale-Up of Family Planning and Adolescent and Youth Sexual and Reproductive Health Services
  • Low-Dose Antenatal Calcium Supplementation: An Intervention Ready for Prime Time
Show more EDITORIAL

Similar Articles

Subjects

  • Health Topics
    • HIV/AIDS
    • Infectious Diseases
Johns Hopkins Center for Communication Programs

Follow Us On

  • LinkedIn
  • Facebook
  • RSS

Articles

  • Current Issue
  • Advance Access Articles
  • Past Issues
  • Topic Collections
  • Most Read Articles
  • Supplements

More Information

  • Submit a Paper
  • Instructions for Authors
  • Instructions for Reviewers

About

  • About GHSP
  • Advisory Board
  • FAQs
  • Privacy Policy
  • Contact Us

© 2025 Creative Commons Attribution 4.0 International License. ISSN: 2169-575X

Powered by HighWire